Better understanding of SARS-CoV-2 mutations to new drugs?
In the analysis of the virus genomes of people with COVID-19 nearly 200 recurring genetic mutations in the Virus were identified, what information on effective drugs and vaccine goals.
In the current study of the University College London are important patterns of diversity of SARS were characterized CoV-2 virus genome, which could contribute to the development of medicinal products or an effective treatment. The results of the study were published in the English journal “Infection, Genetics and Evolution”.
Patterns of diversity of the SARS-CoV-2 virus genome have been characterized for the first time
Through the analysis of the virus genomes of over 7,500 with Covid-19 infected individuals were characterized by the pattern of the diversity of the SARS-CoV-2 virus genome. The study identified 198 recurrent genetic mutations in the Coronavirus show how it adapts possibly to its human hosts, and more developed.
Results indicate a global Transmission to the beginning of the epidemic
The researchers found that a large proportion of the global genetic diversity of SARS-CoV-2 occurs in all heavily affected countries, which suggests a comprehensive global Transmission already at the beginning of the epidemic. In addition, this indicates the Absence of individual patient-zero cases in most of the countries.
Study shows how the Virus adapts
The results of the investigation show that the Virus appeared at the end of the year 2019, before it quickly spread over the whole world. 198 the mutations that have apparently occurred independently more than once, give an indication of how the Virus adapts.
SARS-CoV-2 mutated to a more deadly Virus?
Viruses mutate in a natural way. Mutations are neither good nor bad, but rather indicate how fast or slow a Virus adapts. Up to now, can not be said whether SARS-CoV-2 will be in the future more or less deadly and contagious, report the researchers.
Better targets for treatment identified
The small genetic changes, or mutations, which were identified, were not evenly distributed across the viral genome. Some parts of the genome showed very few mutations, explain the researchers. These unchanging parts of the Virus might be better targets for the development of drugs and vaccines.
Medicines can be due to Mutation ineffective
A major challenge in the fight against a virus is to a vaccine or a drug might be effective if the Virus has mutated. To focus research on parts of the Virus that mutate less likely to be increased to develop the likelihood of drugs that are effective in the long run. There is a need to develop drugs and vaccines that can not be circumvented by the Virus easily, explain the researchers.
When did the Virus for the first time in humans?
The results complement a growing number of Evidence that SARS-CoV-2 viruses have from the end of 2019 from a common ancestor, suggesting that this was the time the Virus from a previous animal host in the people jumped. This means that it is highly unlikely that the CORVID-19-causing was the end of the Virus long before its first detection in humans in circulation, reports the researchers.
Analysis of such an exceptionally high number of virus genomes is extremely advantageous
To be In the first months of the pandemic in the position to analyze such an extraordinary number of virus genomes, it could be for the development of drugs of inestimable value, adds the research group. This shows how far the genome research has come in the last decade. We all benefit from the enormous efforts of hundreds of researchers worldwide, the virus genome sequenced and available online have been made, report the researchers. (as)